Amid a cautious outlook, Biogen has presented new data at the Alzheimer’s Association International Conference (AAIC) 2025, demonstrating that investigational Leqembi 360 mg subcutaneous maintenance ...

Biogen Inc. (NASDAQ:BIIB) is one of the top 10 medical AI companies to buy according to analysts. On July 14, UBS reiterated ...

Subtyping is what made precision medicine in cancer a reality. And for successful drug discovery in all its stages, finding ...

Resting-state EEG (RS-EEG) has emerged as a non-invasive, low-cost tool for Alzheimer’s disease (AD) diagnosis and ...

The Gates Foundation committed $2.5 billion through 2030 to support dozens of different approaches for improving women’s ...

Converging evidence supports a key pathogenic role of the glymphatic system in the accumulation of pathological aggregates in ...

The deal disrupts a long-established practice of the exemption of medicines from tariffs due to their importance in public ...

The First Trust Health Care AlphaDEX ETF (FXH) was launched on May 8, 2007, and is a passively managed exchange traded fund ...

Biogen touts “New Ventures” team; Why drug prices will remain high; San Diego biotech companies struggle to secure funding.

Discover key insights from Supernus Pharmaceuticals' Q2 2025 earnings, including revenue growth, new product launches, the Sage Therapeutics ...

Bakker estimates that hundreds of compounds left on big pharma’s shelves could become much-needed drugs, but she acknowledges ...